to catalyze and strengthen domestic pharmaceutical manufacturing. (7) Identify facilities throughout the United States that can be repurposed to produce advanced pharmaceutical ingredients, especially advanced pharmaceutical ingredients listed on the essential medicines list. (8) Identify partner countries where advanced pharmaceutical ingredients and finished drug products could be manufactured to reduce dependence on China and other countries. (9) Provide recommendations on legislative and regulatory actions that can be taken to address vulnerabilities in the United States pharmaceutical supply chain and increase the number of manufacturers of advanced pharmaceutical ingredients and finished drug products in the United States. (10) Identify and propose steps that can be taken to increase coordination among different Federal and State programs to increase manufacturing of domestic advanced pharmaceutical ingredients and finished drug products. (c) Membership (1) In general The Commission shall be composed of at least 6 but not more than 11 members as follows: (A) The National Security Advisor, who shall serve as co-chair. (B) The White House Domestic Policy Council, who shall serve as co-chair. (C) The Secretary of Health and Human Services. (D) The Secretary of Defense. (E) The Secretary of State. (F) The Secretary of Commerce. (G) Not more than 5 members as may be appointed by joint action of the co-chairs of the Commission, from among the employees and officers of appropriate Federal departments and agencies. (2) Terms Each member shall be appointed for the life of the Commission. (3) Quorum A majority of the Commission shall constitute a quorum but a lesser number may hold hearings. (d) Powers of Commission The Commission may, for the purpose of carrying out this Act, hold hearings, sit and act at times and places, take testimony, and receive evidence as the Commission considers appropriate. (e) Reports (1) In general Not later than 1 year after the date of enactment of this Act, and annually thereafter